News

Stay informed with the latest news updates on local and international events, current affairs, and stories that matter to the public.

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

– Results from the first patient cohort (N=5) of an open-label proof of concept academic study with low-dose IL-2 and

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia Read Post »

News
Exit mobile version